LIBTAYO study results

LIBTAYO helped shrink tumors in some clinical trial patients.

In a clinical trial which included patients with advanced BCC who had been previously treated with a hedgehog inhibitor (HHl):

27 out of 84 patients (32%)
saw an improvement in their locally advanced BCC with LIBTAYO

25%
Of these patients,
21 out of 84 patients (25%)
saw tumors shrink (partial response)
7%
6 out of 84 patients (7%)
saw tumors disappear completely (complete response)
LIBTAYO® (cemiplimab-rwlc) duration of response locally advanced BCC
  • Responses lasted between 2.1 months and 36.8+ months; plus sign [+] means this patient was still responding to treatment at their last assessment

13 out of 54 patients (24%)
saw an improvement in their metastatic BCC with LIBTAYO


23%
Of these patients,
12 out of 54 patients (22%)
saw tumors shrink (partial response)
2%
1 out of 54 patients (2%)
saw tumors disappear completely (complete response)
LIBTAYO® (cemiplimab-rwlc) duration of response metastatic BCC
  • Responses lasted between 4.8 months and 25.8+ months; plus sign [+] means this patient was still responding to treatment at their last assessment

Review the most common side effects of LIBTAYO in this study.